MedTrace Logo

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

NCT00475319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2013-06-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the dose-response of OPC-12759 suspension in dry eye patients

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

placebo

comparison of different dosages of drug

DRUG

1% OPC-12759 ophthalmic suspension

comparison of different dosages of drug

DRUG

2% OPC-12759 ophthalmic suspension

comparison of different dosages of drug

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Satoshi Oshima · Division of dermatologicals and ophthalmologicals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-03-31
Completion
2008-06-30

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00475319 on ClinicalTrials.gov